Free Cardiology CME

  • FREE

    ScientiaCME Cardiology/Pulmonology

    ScientiaCME Cardiology/Pulmonology has two courses at this time:
    Dyslipidemia and atherosclerotic cardiovascular disease (ASCVD): Updates from American Heart Association Scientific Session (AHA) 2016
    Asthma and allergic asthma: personalizing treatment to the patient and therapeutic updates (1 hr CME).
    In order to get credit from ScientiaCME, you must first establish a username and password.

    Target Audience: Physicians specializing in Cardiology, Chest Medicine, Family Medicine, Internal Medicine.

    • Cost: Free
    • Credit hours: 2
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Expiration of CME credit: Two years after release
  • FREE

    Reversal of Novel Oral Anticoagulants (NOACs)

    Reversal of Novel Oral Anticoagulants (NOACs) discusses the problem of reversibility of NOACs and the development of new drugs which can accomplish this reversal.

    By the end of Reversal of Novel Oral Anticoagulants (NOACs), you will be able to:
    • Describe the pharmacodynamics and pharmacokinetics of novel oral anticoagulants (NOACs) with a focus on aspects that impact the reversibility of the drugs
    • Identify the indications for administration of NOAC antidotes or reversal agents, and describe situations in which laboratory testing for coagulation is appropriate
    • Apply NOAC reversal agents to patient cases taking the patient history and clinical presentation into account
    • Describe the mechanisms of action of novel oral anticoagulants and their reversal agents, including universal and class- or drug-specific reversal agents

    Target Audience:
    Cardiologists, trauma surgeons, emergency medicine specialists, intensivists, internists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in anticoagulation, emergency medicine, or critical care; and any other healthcare professionals who clinically encounter patients taking NOACs

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: October 15, 2017
    • Expiration of CME credit: October 15, 2019
  • FREE

    ScientiaCME Treatment strategies in Gaucher disease

    At the conclusion of By the end of Treatment strategies in Gaucher disease, you will be able to:
    • Describe the importance of appropriate GD (Gaucher Disease) diagnosis and treatment (use • for bullets)
    • Determine the likelihood of GD using with established diagnosis methods, given a patient case
    • Describe present therapies for the treatment of GD and the literature supporting their use
    • Design a medical plan to treat a patient with GD, taking into account presently available therapies

    Target Audience:
    Physicians focusing on Cardiology, genetic disorders, hematology, oncology, orthopedics, gastroenterology, neurology and pediatrics.

    • Cost: Free
    • Credit hours: 1.5
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: February 12, 2017
    • Expiration of CME credit: February 12, 2019
  • FREE

    Fabry disease: Updates from the 15th Annual WorldSymposium

    Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels.

    After completing Fabry disease: Updates from the 15th Annual WorldSymposium, physicians will better be able to:

    • Describe the pathogenesis, clinical presentations, complications, and epidemiology of Fabry disease including updated material presented at the 15th Annual WORLDSymposium
    • Describe principles and problems regarding screening for and diagnosing Fabry disease that can applied to patient cases
    • Describe emerging therapies for Fabry disease based on research presented at the 15th Annual WORLDSymposium
    • Design and implement appropriate therapeutic plans for treatment of Fabry disease based on research presented at the 15th Annual WORLDSymposium

     

    Target Audience: cardiologists, nephrologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Fabry disease.

    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: April 18, 2019
    • Expiration of CME credit: April 18, 2020
  • FREE

    Hereditary transthyretin amyloidosis (ATTR) treatment strategies: best practices and emerging therapies

    Transthyretin amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils.

    After completing Hereditary transthyretin amyloidosis (ATTR) treatment strategies: best practices and emerging therapies physicians will better be able to:

    • Describe the pathophysiology of ATTR such that it might inform treatment mechanisms
    • Describe available therapies used for treatment of ATTR and explain current literature supporting use of those therapies
    • Design and implement an appropriate therapeutic plan for treatment of ATTR
    • Describe future therapies currently being investigated for the treatment of ATTR

    Target Audience: neurologists, cardiologists, and hematologists; physician assistants, nurse practitioners, nurses, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.

    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 28, 2019
    • Expiration of CME credit: March 28, 2021
  • FREE

    Updates in the pharmacotherapeutic management of familial hypercholesterolemia (FH): present and emerging treatment options

    Familial hypercholesterolemia (FH), also known as type II hyperlipoproteinemia, is an autosomal dominant disorder characterized by elevated plasma LDL-C levels in the absence of hypertriglyceridemia (or if triglycerides are elevated, they are so independently of FH).

    After completing Updates in the pharmacotherapeutic management of familial hypercholesterolemia (FH): present and emerging treatment options physicians will better be able to:

    • Describe the pathophysiology and genetics of FH such that they might inform treatment mechanisms
    • Describe presently available and emerging treatment options for FH and apply them to patient cases
    • Evaluate a FH treatment plan and suggest modifications for improvement
    • Describe clinical and logistical challenges associated with treating and educating patients with FH

     

    Target Audience: Cardiology and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in cardiology; and any other clinicians with an interest in FH.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: October 22, 2018
    • Expiration of CME credit: October 22, 2020
  • FREE

    Cardiac Imaging: What’s the Right Test for Your Patients?

    This free CME program has two activities and offers 0.50 AMA PRA Category 1 Credits™

    After completing this course, you will better be able to:

    • Determine the most appropriate cardiac imaging tests for the assessment of coronary artery disease in individual patients.
    • Apply evidence to practice regarding the advantages and limitations of SPECT and PET imaging, as well as review the characteristics of agents used for pharmacologic stress testing.
    • Cost: Free
    • Credit hours: 0.5
    • CME credits awarded by: VINDICO Medical Education
    • Format: On-Demand Online, Online Video
    • Expiration of CME credit: 1/14/2020